OPPORTUNITY

The American Cancer Society estimates that in 2017, approximately 253,000 women will be diagnosed with breast cancer in the United States, and about 41,000 women will die from breast cancer. Breast cancer is the second leading cause of cancer death in women. The chance that a woman will die from breast cancer is about 1 in 37 (or about 2.7%). Death rates from breast cancer dropped between 1989 and 2007. This decrease is believed to be the result of early detection through screening and increased awareness, as well as better treatments. Currently, there is no cure for patients with metastatic breast cancer. Therefore, treating patients with early stage breast cancer is an important strategy to reduce the chance of cancer recurrence locally or distally, thereby reducing morbidity and mortality. The commonly used neoadjuvant treatment for breast cancer is TAC [docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide] regimen. Unfortunately, the pathologic complete response, a short-term surrogate marker that is most predictive of long-term survival, is low in patients treated with the TAC regimen, and there is potentially higher toxicity with this treatment.

BREAKTHROUGH IN CANCER THERAPY

Inventors at the University of South Alabama have created a unique combination, neoadjuvant chemotherapeutic regimen for the treatment of multiple cancer types. This “NAC Regimen” has proven particularly effective against triple negative or basal-like breast cancer.

COMPETITIVE ADVANTAGES

•  Treat basal-like or triple negative types of breast cancer

•  Lower toxicity leads to less side effects

INTELLECTUAL PROPERTY STATUS

Patent Issued

Download a PDF version of the description